Set your eyes on us!
Novaliq is a pharmaceutical company for the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol®, the worldwide first water-free technology for ophthalmology.
With an initial focus on DED, Novaliq offers an industry leading portfolio addressing today’s unmet medical needs of millions of eye patients:
NovaTears® improves the signs and symptoms of DED and is marketed under CE-approval in Australia/New Zealand by AFT Pharmaceuticals and in Europe as EvoTears® by Ursapharm.
Two drugs are in the late stage of clinical development with results expected in Q3 2018:
CyclASol®, an anti-inflammatory and immunomodulating drug for the treatment of DED with a demonstrated early onset of action and excellent tolerability, is evaluated in the pivotal phase 2b/3 ESSENCE study.
NOV03, the first drug addressing evaporative DED associated with meibomian gland dysfunction (MGD), is evaluated in the phase 2 SEECASE study.
Headquartered in Heidelberg, Germany, Novaliq has a scientific office in Cambridge, MA in USA. The long-term shareholder is dievini, Hopp BioTech holding, an active investor in Life and Health Sciences companies.